
Deepika Dhawan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5008428/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, <i>BRAF</i> -mutated Urothelial Carcinoma. Molecular Cancer Therapeutics, 2021, 20, 2177-2188.	4.1	13
2	RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors. BMC Cancer, 2020, 20, 251.	2.6	16
3	Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model. Bladder Cancer, 2019, 5, 63-71.	0.4	9
4	Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. Frontiers in Oncology, 2019, 9, 1493.	2.8	51
5	Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma. Oncotarget, 2018, 9, 37042-37053.	1.8	12
6	Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model forÂEmerging Therapies. Bladder Cancer, 2018, 4, 149-159.	0.4	27
7	Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. PLoS Genetics, 2018, 14, e1007571.	3.5	33
8	Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. International Journal of Genomics, 2017, 2017, 1-9.	1.6	40
9	Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging. International Journal of Nanomedicine, 2016, Volume 11, 4141-4155.	6.7	46
10	Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test. Molecular Cancer Research, 2015, 13, 993-1002.	3.4	117
11	Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. PLoS ONE, 2015, 10, e0136688.	2.5	56
12	"Lassie,―"Toto,―and Fellow Pet Dogs: Poised to Lead the Way for Advances in Cancer Prevention. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e667-e672.	3.8	12
13	Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development. ILAR Journal, 2014, 55, 100-118.	1.8	202
14	DNMT1: An emerging target in the treatment of invasive urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1761-1769.	1.6	34
15	Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer. Cancer Research, 2013, 73, 875-884.	0.9	52
16	Subcutaneous 5-Azacitidine Treatment of Naturally Occurring Canine Urothelial Carcinoma: A Novel Epigenetic Approach to Human Urothelial Carcinoma Drug Development. Journal of Urology, 2012, 187, 302-309.	0.4	42
17	Effects of Short-term Celecoxib Treatment in Patients with Invasive Transitional Cell Carcinoma of the Urinary Bladder. Molecular Cancer Therapeutics, 2010, 9, 1371-1377.	4.1	50
18	Canine invasive transitional cell carcinoma cell lines: In vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 284-292.	1.6	47

#	Article	IF	CITATIONS
19	Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Molecular Cancer Therapeutics, 2008, 7, 897-904.	4.1	39